Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Home
  • Home
Hostname: page-component-559fc8cf4f-28jzs Total loading time: 0.31 Render date: 2021-03-02T14:00:46.999Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": false, "newCiteModal": false, "newCitedByModal": true }
EnglishFrançais
Journal of Law, Medicine & Ethics Journal of Law, Medicine & Ethics

Article contents

Designing a Delinked Incentive for Critical Antibiotics: Lessons from Norway

Published online by Cambridge University Press:  01 January 2021

Christine Årdal ,
Jostein Johnsen  and
Karianne Johansen
Get access
Rights & Permissions[Opens in a new window]

Extract

No country has yet implemented a pilot to ensure access to or the innovation of new antibiotics for multi-drug infections. A team from national health agencies in Norway, with the support of the Innovative Medicine Initiative-funded project DRIVE-AB, designed a model suitable for the national context, including the selection of the antibiotics, the potential value, and the operational model.

Type
Symposium Articles
Information
Journal of Law, Medicine & Ethics , Volume 46 , Issue S1: Incentives to Stimulate Research and Development of New Antibiotics: Detailed Assessments of Select Incentives and Models , Spring 2018 , pp. 43 - 49
Copyright
Copyright © American Society of Law, Medicine and Ethics 2018

Access options

Get access to the full version of this content by using one of the access options below.
If you should have access and can't see this content please contact technical support.

References

Laxminarayan, R. et al., “Antibiotic Resistance: The Need for Global Solutions,” Lancet Infectious Diseases 13, no. 12 (2013): 1057–1098.Google Scholar
Holmes, A. H. et al., “Understanding the Mechanisms and Drivers of Antimicrobial Resistance,” The Lancet 387, no. 10014 (2016): 176–187.Google Scholar
Laxminarayan, R., “Antibiotic Effectiveness: Balancing Conservation against Innovation,” Science 345, no. 6202 (2014): 1299–1301.Google Scholar
Silver, L. L., “Challenges of Antibacterial Discovery,” Clinical Microbiology Reviews 24, no. 1 (2011): 71–109.CrossRefGoogle Scholar
Pew Charitable Trust, Antibiotics Currently in Clinical Development, available at <http://www.pewtrusts.org/en/multimedia/data-visualizations/2014/antibiotics-currently-in-clinical-development> (last visited October 6, 2017).+(last+visited+October+6,+2017).>Google Scholar
DRIVE-AB, Work Package 2, Task 3: Identified Risks and Bottlenecks to Antibiotics Innovation (2015), available at <http://drive-ab.eu/wp-content/uploads/2014/09/Report-Bottlenecks-and-risks-DRIVE-AB-Task-3-20151023-FINAL.pdf> (last visited January 11, 2018).+(last+visited+January+11,+2018).>Google Scholar
AMR Review, Tackling Drug-Resistant Infections Globally: Final Report and Recommendations (2016), available at <https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf> (last visited January 11, 2018)+(last+visited+January+11,+2018)>Google Scholar
Daniel, G. et al., “Addressing Antimicrobial Resistance and Stewardship: The Priority Antimicrobial Value and Entry (PAVE) Award,” JAMA 318, no. 12 (2017): 1103–1104.Google Scholar
The Boston Consulting Group, Breaking through the Wall: A Call for Concerted Action on Antibiotics Research and Development (2017), available at <http://www.bundesgesundheitsministerium.de/service/publikationen/gesundheit/details.html?bmg%5bpubid%5d=3006> (last visited January 11, 2018).+(last+visited+January+11,+2018).>Google Scholar
Folkhalsomyndigheten, Analys av förutsättningar för att testa en ny ersättningsmodell för antibiotika (2016), available at <https://www.folkhalsomyndigheten.se/publicerat-material/publikationsarkiv/a/analys-av-forutsattningar-for-att-testaen-ny-ersattningsmodell-for-antibiotika/> (last visited Jan. 11, 2018).+(last+visited+Jan.+11,+2018).>Google Scholar
Legemiddelforbruk.no, Drug Consumption in Norway, available at <http://www.legemiddelforbruk.no/> (last visited May 1, 2017).+(last+visited+May+1,+2017).>Google Scholar
Norwegian Competence Center for Antibiotic Use for Specialist Health Services, Nasjonal faglig retningslinje for bruk av antibiotika i sykehus, available at <https://helsedirektoratet.no/retningslinjer/antibiotika-i-sykehus> (last visited May 1, 2017).+(last+visited+May+1,+2017).>Google Scholar
Norwegian Medicines Agency, Find Medicine, available at <http://www.legemiddelverket.no> (last visited Dec. 1, 2017).+(last+visited+Dec.+1,+2017).>Google Scholar
Mosley, J. F. et al., “Ceftazidime-Avibactam (Avycaz): For the Treatment of Complicated Intra-Abdominal and Uri-nary Tract Infections,” Pharmacy and Therapeutics 41, no. 8 (2016): 479.Google Scholar
ECDC, Surveillance of Antimicrobial Consumption in Europe (2012), available at <https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/antimicrobial-consumption-europe-esac-net-2012.pdf> (last visited Jan. 11, 2018).+(last+visited+Jan.+11,+2018).>Google Scholar
NORM/NORM-VET, Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway (2015), available at <https://unn.no/Documents/Kompetansetjenester,%20-sentre%20og%20fagr%C3%A5d/NORM%20-%20Norsk%20overv%C3%A5kingssystem%20for%20anti-biotikaresistens%20hos%20mikrober/Rapporter/NORM_NORM-VET-2015.pdf> (last visited Jan. 11, 2018).+(last+visited+Jan.+11,+2018).>Google Scholar
Alberg, T. et al., “Antibiotikabruk og infeksjoner i sykehjem,” Tidsskr Nor Laegeforen 137, no. 6 (2017): 424.Google Scholar
Statens legemiddelverk, Legemiddelmangel og avregistre-ringer 2017: Råd til apotek og helsepersonell, available at <https://legemiddelverket.no/legemiddelmangel/legemiddelmangel-og-avregistreringer-2017-rad-til-apotek-og-helsepersonell> (last visited April 27, 2017).+(last+visited+April+27,+2017).>Google Scholar
ECDC, Rapid Risk Assessment: Carbapenem-Resistant Enterobacteriaceae (2016), available at <https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/carbapenem-resistant-enterobacteriaceae-risk-assessment-april-2016.pdf> (last visited January 11, 2018).+(last+visited+January+11,+2018).>Google Scholar
Årdal, C. et al., DRIVE-AB Final Report - Revitalizing the Antibiotic Pipeline: Stimulating Innovation While Driving Sustainable Use and Global Access (2018), available at <http://www.imi.europa.eu/projects-results/project-fact-sheets/drive-ab> (last visited January 24, 2018)+(last+visited+January+24,+2018)>Google Scholar
Årdal, C. et al., “An Antibiotic's Journey from Marketing Authorization to Use, Norway,” Bulletin of the World Health Organization 95, no. 3 (2017): 220.CrossRefGoogle Scholar
Central Drugs Standard Control Organization, List of New Drug Approved from 01-01-2017 to Till Date by New Drugs Division, available at <http://cdsco.nic.in/forms/list.aspx?lid=2034&Id=11> (last visited May 8, 2017).+(last+visited+May+8,+2017).>Google Scholar
South African Medicine Price Registry, Database Of Medicine Prices 08th May 2017 (2017), available at <http://mpr.gov.za/PublishedDocuments.aspx> (last visited January 11, 2018).+(last+visited+January+11,+2018).>Google Scholar
The World Bank, Health Expenditure, Public (% of GDP), available at <http://data.worldbank.org/indicator/SH.XPD.PUBL.ZS> (last visited May 2, 2017).+(last+visited+May+2,+2017).>Google Scholar
Seya, M.-J. et al., “A First Comparison between the Consumption of and the Need for Opioid Analgesics at Country, Regional, and Global Levels,” Journal of Pain & Palliative Care Pharmacotherapy 25, no. 1 (2011): 6–18.CrossRefGoogle Scholar

Altmetric attention score

Full text views

Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.

Total number of HTML views: 7
Total number of PDF views: 1 *
View data table for this chart

* Views captured on Cambridge Core between 01st January 2021 - 2nd March 2021. This data will be updated every 24 hours.

2 Cited by

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Designing a Delinked Incentive for Critical Antibiotics: Lessons from Norway
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Designing a Delinked Incentive for Critical Antibiotics: Lessons from Norway
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Designing a Delinked Incentive for Critical Antibiotics: Lessons from Norway
Available formats
×
×

Reply to: Submit a response

Your details

Conflicting interests

Do you have any conflicting interests? *